Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 14

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 14
---
,211    | ) |     |               |    (572,211 | ) |
| Balance                            
 at February 13, 2024 (Predecessor) |     |                 | 5,155,703 |     | $      | 4,077,560 |     |        | 22,764,764 |     | $      | 38,023,784 |     |        | 292 |     | $      | - |     | $          | 1,036,557 |     | $           | (43,662,032 | ) |     | $             | (42,625,475 | ) |

<div align='center'>See accompanying notes to the condensed consolidated financial statements

Reflects a 1-for-100 reverse stock split effective January 8, 2025 and 1-for-20 reverse stock split effective June 13, 2025

4

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)</div>

|                                                                                |     | For the    
 Six Months 
 ended      
 June 30,   
 2025       |             |   |     | For the      
 Period from  
 February 14, 
 2024 through 
 June 30,     
 2024         |            |   |     | For the      
 Period from  
 January 1,   
 2024 through 
 February 13, 
 2024         |           |   |
|:-------------------------------------------------------------------------------|:----|:-----------|------------:|:--|:----|:-------------|-----------:|:--|:----|:-------------|----------:|:--|
|                                                                                |     | -Successor |             |   |     | -Successor   |            |   |     | -Predecessor |           |   |
| Cash flows from operating activities:                                          |     |            |             |   |     |              |            |   |     |              |           |   |
| Net loss                                                                       |     | $          | (10,523,246 | ) |     | $            | (4,176,137 | ) |     | $            |  (572,211 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities:    |     |            |             |   |     |              |            |   |     |              |           |   |
| Gain from settlement